Investors Invited to Take Charge in Aquestive Therapeutics Securities Fraud Case

Investors Rally in the Fight Against Securities Fraud at Aquestive Therapeutics

In a notable development, the Rosen Law Firm, renowned for its commitment to investor rights, has issued a crucial reminder for individuals who purchased securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between June 16, 2025, and January 8, 2026. If you fall within this time frame, you may have the opportunity to participate in a class action lawsuit regarding securities fraud and potentially secure compensation for losses incurred.

The Importance of the Class Period

The lawsuit relates specifically to a Class Period that spans from June 16, 2025, to January 8, 2026. It is during this period that significant allegations have arisen concerning the misleading statements and lack of transparency made by the defendants regarding the company's New Drug Application (NDA) for its product, Anaphylm. Investors who purchased shares during this timeframe are encouraged to take action, as valuable rights may be at stake.

What Investors Should Know

The lead plaintiff motion must be filed by May 4, 2026, to act as a representative in the ongoing lawsuit. Interested parties can sign up and get more information through the Rosen Law Firm’s detailed webpage or reach out to Phillip Kim, Esq., for assistance. Remarkably, those joining the class action are not required to bear any out-of-pocket fees or costs, thanks to a contingency fee arrangement that ensures legal representation is accessible.

For many investors, joining this class action represents a pivotal moment to hold accountable those responsible for the company's failure to disclose critical information pertaining to the NDA, especially as it relates to packaging, administration, and use of the product.

Why Choose Rosen Law Firm?

Navigating a class action can be daunting, especially for those less familiar with the legal framework. Rosen Law Firm stands out among many firms due to its proven track record in successfully leading securities class actions. The firm has achieved significant settlements and holds a strong reputation within the investor community. Notably, it was ranked as the top firm for securities class action settlements in 2017 and has consistently secured hundreds of millions in recovery for investors over the years.

Investors are advised to choose legal counsel wisely. Many firms that send notices may lack the experience or resources necessary for effective representation, functioning instead as intermediaries. Seeking a capable legal partner can make a substantial difference in the outcome of these cases.

Allegations and Investor Impact

This class action lawsuit centers on the allegation that Aquestive Therapeutics failed to disclose essential details of its NDA process, essentially downplaying significant human factors related to its sublingual film. This lack of transparency, when revealed to the market, led to substantial financial damage for investors who relied on the company's statements.

Among the concerns raised are the implications of improper packaging and labeling of the product, which potentially jeopardize user safety and efficacy. Investors must stay informed about these developments, as they impact the legitimacy of the company's operations and their financial investments.

Next Steps for Investors

If you believe you qualify for the class action, directions on how to participate can be found on the Rosen Law Firm’s dedicated website. The firm encourages investors to not wait, as time is of the essence with the deadline of May 4, 2026, fast approaching.

Additionally, while no class has yet been certified, the options available include selecting independent counsel or remaining a passive member of the class. Regardless of a decision to actively participate or not, it is essential to stay updated on the progress of the case.

Follow Rosen Law Firm for real-time updates on LinkedIn, Twitter, and Facebook, ensuring you remain informed about crucial developments that could affect your potential recovery. If you suffered losses during the identified Class Period, now is the time to act.